Breaking News Instant updates and real-time market news.

ESPR

Esperion

$41.90

4.92 (13.30%)

17:13
10/28/18
10/28
17:13
10/28/18
17:13

Esperion announces positive top-line results from Phase 3 Bempedoic Acid study

Esperion announced positive top-line results from its global, pivotal Phase 3 clinical study. This trial was a 52-week, randomized, double-blind, placebo-controlled study to evaluate the LDL-C lowering efficacy and the safety and tolerability of bempedoic acid 180 mg compared to placebo in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia. These results complete our global pivotal phase 3 LDL-C lowering development program of bempedoic acid. The study included 779 high cardiovascular risk patients taking maximally tolerated statins who required additional LDL-C lowering. The study achieved its efficacy endpoints and other key measures at 12 weeks, including: On-treatment LDL-C lowering of an additional 18%, and in the intent to treat analysis, LDL-C lowering of an additional 17%; Reduction of 19% in high-sensitivity C-reactive protein, an important marker of the underlying inflammation associated with cardiovascular disease; Reduction in hemoglobin A1c of 0.21% vs. placebo in patients with diabetes; Safety and Tolerability of Bempedoic Acid Over 52 Weeks. In this study, bempedoic acid was observed to be safe and well-tolerated. The results showed no clinically relevant differences between the bempedoic acid and placebo treatment groups in the occurrence of adverse events with 70% and 71%, respectively; serious adverse events with 20% and 19%, respectively; discontinuations due to AEs with 11% and 9%, respectively; fatal adverse events with 1.1% and 0.8%, respectively. No fatal adverse events were determined to be related to study medication. CV deaths were balanced between the study arms. The bempedoic acid arm included a case of gas poisoning and a case of sepsis as a complication of planned abdominal surgery. No fatal AEs due to neoplasms. Esperion plans to submit New Drug Applications to the U.S. Food and Drug Administration for bempedoic acid and the bempedoic acid / ezetimibe combination pill for LDL-C-lowering indications during the first quarter of 2019. Additionally, Esperion plans to submit Marketing Authorization Applications to the European Medicines Agency during the second quarter of 2019.

  • 11

    Nov

  • 12

    Nov

ESPR Esperion
$41.90

4.92 (13.30%)

08/17/18
08/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nvidia (NVDA) upgraded to Outperform from Perform at Oppenheimer with analyst Rick Schafer noting that all its segments grew year-over-year, led by core Gaming and Data Center. 2. Esperion (ESPR) upgraded to Buy from Neutral at Citi with analyst Joel Beatty saying he believes bempedoic acid for LDL-lowering is likely to be approved. 3. Viper Energy (VNOM) upgraded to Buy from Hold at Stifel with analyst Timothy Howard saying he believes the MLP will be a significant beneficiary of parent Diamondback Energy's (FANG) acquisition of Energen (EGN). 4. First Data (FDC) upgraded to Overweight from Neutral at Atlantic Equities with analyst Kunaal Malde saying its prior acquisitions of CardConnect and BluePay have given it a foothold in higher growth segments and the company is now "on a clear path to deleveraging." 5. Fluor (FLR) upgraded to Buy from Hold at Canaccord. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/17/18
08/17/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. NVIDIA UPGRADED AMID POST-EARNINGS PULLBACK: Oppenheimer analyst Rick Schafer upgraded Nvidia to Outperform from Perform following Thursday's earnings, noting that all its segments grew year-over-year, led by core Gaming and Data Center. While its Q3 outlook was mixed, he attributes the modest top-line guidance miss to a slowdown in crypto demand and lack of volume availability of the recently introduced Turing gaming GPU. Schafer, who he sees significant pent-up demand for Turing along with solid, structural growth drivers in Data Center AI, gaming and autonomous, set a $310 price target on Nvidia shares, which are down 4.3% to $246.27 in morning trading. CITI SAY BUY ESPERION AHEAD OF EXPECTED CHOLESTEROL DRUG APPROVAL: Citi analyst Joel Beatty upgraded Esperion to Buy from Neutral because he believes bempedoic acid for LDL-lowering is likely to be approved. His 70% probability of approval view is higher than the roughly 40% odds of success he believes is currently priced in the stock, Beatty tells investors. DSW CUT TO NEGATIVE: Susquehanna analyst Sam Poser downgraded DSW to Negative from Neutral as he expects margins to be challenged due to increased variable costs and gross margin pressure related to the new loyalty program. He also expects guidance to be reduced following the next earnings call. Poser lowered his price target to $22 from $26 on DSW shares, which are down 7.3% in morning trading. DEUTSCHE MORE POSITIVE ON MATCH GROUP: Deutsche Bank analyst Kunal Madhukar believes the total addressable market for Match Group's Tinder could be in the range of 185-190M monthly average users, which could translate into about 10M paying subscribers for Tinder, and he contends that Tinder remains underpenetrated relative to that opportunity. Given his higher confidence in Tinder's ability to keep delivering strong growth over the medium-term, Madhukar reiterated his Buy rating on Match Group and increased his price target on the shares to $56 from $50.
09/13/18
STFL
09/13/18
INITIATION
STFL
Buy
Esperion resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of Esperion with a Buy rating and $89 price target, saying he is positively biased heading into bempedoic acid's Study 2 results expected in October. Archila believes the death imbalance for fatal adverse events unrelated to drug is "most likely noise", the controversy surrounding increases in liver function tests is "overblown", and there is a "clear role for BPA and BPA/ezetimibe within their treatment armamentarium for statin intolerant/uncontrolled patients."
10/16/18
BTIG
10/16/18
INITIATION
Target $82
BTIG
Buy
Esperion initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Esperion (ESPR) with a Buy rating and a price target of $82, saying that with its development of bempedoic acid, or BA, to reduce cholesterol, the next key question is about the drug's safety. The analyst notes that while the data from Study 1 in May were disappointing, Study 2 readout in the next few weeks should have more answers. Shrader adds that the introduction of "non-stain" into the cholesterol market has already worked for Merck's (MRK) Zetia, and if BA is perceived well on its safety profile, it is "highly supportive" of its investment story.

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

12:59
01/19/19
01/19
12:59
01/19/19
12:59
Periodicals
Tencent not the best opportunity out there right now, Barron's says »

After securing a billion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

12:53
01/19/19
01/19
12:53
01/19/19
12:53
Periodicals
Bae Systems will mount new charge, Barron's says »

Bae Systems has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

, COST

Costco

$213.59

2.15 (1.02%)

12:50
01/19/19
01/19
12:50
01/19/19
12:50
Periodicals
Costco might be 'good buy' following 2018 pullback, Barron's says »

Part of what makes Costco…

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

COST

Costco

$213.59

2.15 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

VNO

Vornado

$66.40

1.04 (1.59%)

, KRC

Kilroy Realty

$68.23

0.21 (0.31%)

12:45
01/19/19
01/19
12:45
01/19/19
12:45
Periodicals
Kilroy, Vornado Realty have 'solid' prospects, Barron's says »

Office REITs have been…

VNO

Vornado

$66.40

1.04 (1.59%)

KRC

Kilroy Realty

$68.23

0.21 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

GOLD

Barrick Gold

$11.78

-0.11 (-0.93%)

, GG

Goldcorp

$10.37

0.04 (0.39%)

12:41
01/19/19
01/19
12:41
01/19/19
12:41
Periodicals
Gold mining stocks 'an unalloyed bargain,' Barron's says »

Two multibillion-dollar…

GOLD

Barrick Gold

$11.78

-0.11 (-0.93%)

GG

Goldcorp

$10.37

0.04 (0.39%)

NEM

Newmont Mining

$31.77

0.15 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TECH

Bio-Techne

$163.24

1.16 (0.72%)

, A

Agilent

$71.93

1.16 (1.64%)

12:29
01/19/19
01/19
12:29
01/19/19
12:29
Periodicals
Rising demand benefiting Illumina, Thermo Fisher, Barron's says »

Healthy funding and…

TECH

Bio-Techne

$163.24

1.16 (0.72%)

A

Agilent

$71.93

1.16 (1.64%)

DHR

Danaher

$107.43

1.88 (1.78%)

TMO

Thermo Fisher

$240.72

2.55 (1.07%)

ILMN

Illumina

$312.66

2.53 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 05

    Feb

ATVI

Activision Blizzard

$48.64

1.26 (2.66%)

, EA

Electronic Arts

$92.50

3.19 (3.57%)

12:22
01/19/19
01/19
12:22
01/19/19
12:22
Periodicals
EA, Activision struggling to survive a Fortnite World, Barron's says »

Netflix (NFLX) delivered…

ATVI

Activision Blizzard

$48.64

1.26 (2.66%)

EA

Electronic Arts

$92.50

3.19 (3.57%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 12

    Feb

  • 25

    Feb

AIMT

Aimmune

$22.90

0.26 (1.15%)

, CELG

Celgene

$86.27

-0.32 (-0.37%)

09:01
01/19/19
01/19
09:01
01/19/19
09:01
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AIMT

Aimmune

$22.90

0.26 (1.15%)

CELG

Celgene

$86.27

-0.32 (-0.37%)

BIIB

Biogen

$337.46

-0.93 (-0.27%)

CMRE

Costamare

$4.97

0.09 (1.84%)

DAC

Danaos

$0.90

0.05 (5.88%)

DCIX

Diana Containerships

$0.90

-0.02 (-2.17%)

TGH

Textainer

$13.34

0.57 (4.46%)

NM

Navios Maritime

$2.73

-0.04 (-1.44%)

YRCM

Rogers Cantel

$0.00

(0.00%)

EXPD

Expeditors

$69.34

1.43 (2.11%)

LEN

Lennar

$44.11

-0.64 (-1.43%)

KBH

KB Home

$20.30

-0.28 (-1.36%)

PHM

PulteGroup

$26.58

-0.27 (-1.01%)

Z

Zillow

$33.93

0.35 (1.04%)

ZG

Zillow

$33.74

0.35 (1.05%)

RLGY

Realogy

$18.27

-0.155 (-0.84%)

RDFN

Redfin

$18.49

0.48 (2.67%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.78

0.16 (0.96%)

F

Ford

$8.59

0.23 (2.75%)

GM

General Motors

$38.63

0.35 (0.91%)

HMC

Honda

$29.77

0.22 (0.74%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$125.40

0.505 (0.40%)

VLKAY

Volkswagen

$0.00

(0.00%)

VC

Visteon

$76.43

4.85 (6.78%)

ADNT

Adient

$19.78

1.59 (8.74%)

AXL

American Axle

$14.62

0.45 (3.18%)

DLPH

Delphi Technologies

$15.94

0.44 (2.84%)

APTV

Aptiv

$72.91

1.77 (2.49%)

BWA

BorgWarner

$40.60

0.54 (1.35%)

LEA

Lear

$151.67

0.98 (0.65%)

TEN

Tenneco

$34.61

1.125 (3.36%)

MGA

Magna

$50.91

0.78 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 06

    Feb

  • 07

    Feb

  • 14

    Feb

  • 19

    Feb

  • 25

    Apr

  • 18

    May

  • 28

    May

  • 24

    Jul

  • 23

    Oct

ASLN

Aslan Pharmaceuticals

$3.55

(0.00%)

, FPRX

Five Prime

$11.20

0.53 (4.97%)

04:55
01/19/19
01/19
04:55
01/19/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

ASCO GI 2019 Symposium…

ASLN

Aslan Pharmaceuticals

$3.55

(0.00%)

FPRX

Five Prime

$11.20

0.53 (4.97%)

KURA

Kura Oncology

$15.70

-0.06 (-0.38%)

ZLAB

Zai Lab

$25.98

-0.05 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/19/19
01/19
04:55
01/19/19
04:55
Conference/Events
Deutsche Bank to hold a conference »

17th Annual dbAccess…

TCCO

Technical Comm Corp

$2.61

-0.19 (-6.79%)

18:02
01/18/19
01/18
18:02
01/18/19
18:02
Hot Stocks
Technical Comm Corp reports notice of failure to satisfy Nasdaq rule »

Technical Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$6.19

0.455 (7.93%)

17:38
01/18/19
01/18
17:38
01/18/19
17:38
Periodicals
Snap exec fired due to undisclosed relationship with consultant, Cheddar says »

Snap's global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 03

    Mar

SSW

Seaspan

$9.16

0.16 (1.78%)

17:33
01/18/19
01/18
17:33
01/18/19
17:33
Syndicate
Breaking Syndicate news story on Seaspan »

Seaspan files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.38

0.75 (1.54%)

17:30
01/18/19
01/18
17:30
01/18/19
17:30
Hot Stocks
Textron subsidiary awarded $439.56M government contract modification »

Bell Helicopter Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TAC

TransAlta

$4.91

0.04 (0.82%)

17:28
01/18/19
01/18
17:28
01/18/19
17:28
Hot Stocks
Mangrove Partners reports 9.4% passive stake in TransAlta »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDS

Telephone and Data

$36.27

0.42 (1.17%)

17:27
01/18/19
01/18
17:27
01/18/19
17:27
Hot Stocks
Telephone and Data's Meyers sells 80,465 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$137.24

2.59 (1.92%)

17:03
01/18/19
01/18
17:03
01/18/19
17:03
Syndicate
Breaking Syndicate news story on GW Pharmaceuticals »

GW Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCSC

Fibrocell Science

$2.03

0.03 (1.50%)

16:55
01/18/19
01/18
16:55
01/18/19
16:55
Syndicate
Breaking Syndicate news story on Fibrocell Science »

Fibrocell Science files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

, ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Conference/Events
EnLink Midstream Partners to hold a special shareholder meeting »

Special Shareholder…

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

FDX

FedEx

$176.97

3.72 (2.15%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Hot Stocks
FedEx establishes voluntary buyout program for U.S. workers »

FedEx said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

  • 03

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

, ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

16:48
01/18/19
01/18
16:48
01/18/19
16:48
Conference/Events
EnLink Midstream Companies to hold a special shareholder meeting »

Special Shareholder…

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

MKL

Markel

$1,067.03

13.52 (1.28%)

16:36
01/18/19
01/18
16:36
01/18/19
16:36
Hot Stocks
Markel says Anthony Belisle, Alissa Fredricks no longer with company »

Markel Corporation said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NILSY

Norilsk Nickel

$0.00

(0.00%)

16:35
01/18/19
01/18
16:35
01/18/19
16:35
Downgrade
Norilsk Nickel rating change at Goldman Sachs »

Norilsk Nickel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

, ABBV

AbbVie

$89.51

2.28 (2.61%)

16:33
01/18/19
01/18
16:33
01/18/19
16:33
Hot Stocks
AbbVie: Phase 3 study of ibrutinib did not meet primary endpoint »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

ABBV

AbbVie

$89.51

2.28 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 18

    Feb

  • 18

    May

FOMX

Foamix

$3.70

-0.14 (-3.65%)

16:32
01/18/19
01/18
16:32
01/18/19
16:32
Conference/Events
Foamix to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.